Overview

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Status:
Completed
Trial end date:
2019-11-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Canadian Cancer Trials Group
Collaborator:
Innate Pharma